Publications by authors named "Matthew Zirwas"

Claim this Profile
T
Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.
Linda Stein Gold, James Del Rosso, Benjamin D Ehst, Matthew J Zirwas, Lawrence J Green

J Dermatolog Treat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and healthcare provider perspectives on treatment patterns and patient satisfaction of seborrheic dermatitis in the United States.
Raj Chovatiya, Christy H Chang, Lakshi Aldredge, Candrice Heath, Moises Acevedo, Matthew Zirwas

J Dermatolog Treat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.
Andrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, James Q Del Rosso, Zoe D Draelos, Matthew J Zirwas

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined impact of lesion and itch severity on initiation of biologic treatment in patients with moderate or severe atopic dermatitis from specialty dermatology facilities in the United States.
Gil Yosipovitch, Matthew Zirwas, Lawrence Rasouliyan, Amanda G Althoff, Danae A Black

J Am Acad Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare Resource Utilization and Economic Burden Across Clinical Phenotypes of Moderate-to-Severe Atopic Dermatitis in United States Dermatology Facilities.
Matthew Zirwas, Peter Lio, Lawrence Rasouliyan, Amanda G Althoff, Danae A Black

Dermatol Ther (Heidelb)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I Silverberg, Kim A Papp, Matthew Zirwas

J Eur Acad Dermatol Venereol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of Atopic Dermatitis in Patients Initiating Systemic Therapies in the United States.
Matthew Zirwas, Nicole Princic, Megan K Richards, Aamir Qureshi, Lorenzo Sabatelli

Adv Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA).
Jennifer Soung, Vivian Laquer, Matthew Zirwas, Peter van Iperen, John C Stinson

Dermatol Ther (Heidelb)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study.
Matthew Zirwas, Joseph F Fowler, Athanasios Tsianakas, Alim R Devani, Philippa Halden

J Am Acad Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis.
Omar Alani, David Wang, Samer Wahood, Sabine Obagi, Diego Dasilva, Matthew J Zirwas

J Drugs Dermatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpreting Safety Analyses in Psoriasis Clinical Trials.
Matthew Zirwas, Cynthia Trickett, Joe Gorelick, Kejia Wang, Keith Wittstock

J Clin Aesthet Dermatol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and Healthcare Provider Perspectives on the Pathway to Diagnosis of Seborrheic Dermatitis in the United States.
Raj Chovatiya, Meredith T Polaskey, Lakshi Aldredge, Candrice Heath, Moises Acevedo, Matthew Zirwas

Adv Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).
Brett King, Maryanne M Senna, Natasha A Mesinkovska, Charles Lynde, Matthew Zirwas

J Am Acad Dermatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and Healthcare Provider Perspectives on Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey.
Meredith T Polaskey, Lakshi Aldredge, Candrice Heath, Moises Acevedo, David H Chu, Matthew Zirwas

Dermatol Ther (Heidelb)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical Treatment of Atopic Dermatitis: An Adherence-Based Appraisal of the AAD Guidelines.
Max Oscherwitz, Aditi Gadre, Anna Martino, Matthew Zirwas, Steven Feldman

J Drugs Dermatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Safety and Tolerability of Lumify Eye Illuminations Cosmetic Products.
Gina Wesley, Melissa Morrison Toyos, Melinda M DiVito, Matthew Zirwas

Clin Ophthalmol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethics of Managing Recalcitrant Eczematous Dermatitis in Adults.
Akash Rau, Matthew Zirwas, Jane M Grant-Kels, Jenny E Murase

Dermatitis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
Linda Stein Gold, David N Adam, Lorne Albrecht, Javier Alonso-Llamazares, Laura K Ferris, Matthew Zirwas

J Am Acad Dermatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia, Matthew Zirwas

J Am Acad Dermatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis.
Leon Kircik, Matthew Zirwas, Shawn G Kwatra, G Michael Lewitt, Holly Glover

Dermatol Ther (Heidelb)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade.
Jordan Bury, Matthew Zirwas

J Drugs Dermatol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani, Matthew Zirwas

Br J Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Matthew J Zirwas, Zoe D Draelos, Janet DuBois, Leon H Kircik, Angela Y Moore

JAMA Dermatol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.
Elizabeth Mancuso-Stewart, Jaimie Rodger, Matthew Zirwas

Skinmed· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.
Melinda Gooderham, Leon Kircik, Matthew Zirwas, Mark Lee, Steven Kempers

J Drugs Dermatol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis